This article was originally posted Dec. 21.
Idaho Technology said this week that it has signed a licensing agreement with Bio-Rad Laboratories relating to the use of SYBR Green in PCR and high-resolution melting.
The arrangement is the latest in a spate of intellectual property licensing agreements that Idaho Technology has made with various biotechnology companies in relation to the SYBR Green technology over the last several years.
Most recently, in August, Idaho Tech said that it had licensed reagents and methods using SYBR Green 1 and post-PCR melt curve analysis to DuPont's Qualicon business, which is using the technology to develop real-time PCR and melt curve assays on its BAX System for pathogen detection in food (PCR Insider, 8/5/10).
At the time, Idaho Tech said that it had completed similar agreements with two other undisclosed companies in the life science research sector.
Idaho Tech has an exclusive licensing agreement with the University of Utah Research Foundation for patents surrounding the use of SYBR Green in PCR applications; as well as an agreement to package those with key patents owned by Evotec and licensed to Roche, and related to post-PCR melting curve analysis, Jill Powlick, legal counsel for Idaho Tech, said at the time.
In January, Idaho Tech inked a cross-licensing pact with Life Technologies' Applied Biosystems business in which Idaho obtained the right to use the TaqMan 5' nuclease process, and ABI obtained the right to use SYBR Green in PCR (PCR Insider, 1/28/10).
Idaho Tech has reached similar licensing deals with Qiagen, Thermo Fisher Scientific, and Finnzymes, now part of Thermo Fisher; as well as with Cepheid to settle a patent-infringement Idaho Tech brought against Cepheid in 2007. Meantime, Roche has also licensed the combined SYBR Green and melting curve package to companies such as Takara Bio and Kapa Biosystems.
It was immediately unclear how Bio-Rad is using or plans to use the SYBR Green technology. Company officials were not immediately available for comment. Financial terms of the agreement were not disclosed.